Résumé
The mechanisms of colostrum-mediated virus transmission are difficult to elucidate because of the absence of experimental animal models and the difficulties in tissue sample collection from mothers in the peripartum period. Porcine epidemic diarrhea virus (PEDV) is a reemerging enteropathogenic coronavirus that has catastrophic impacts on the global pig industry. PEDV primarily infects neonatal piglets by multiple routes, especially 1- to 2-day-old neonatal piglets. Here, our epidemiological investigation and animal challenge experiments revealed that PEDV could be vertically transmitted from sows to neonatal piglets via colostrum, and CD3+ T cells in the colostrum play an important role in this process. The results showed that PEDV colonizing the intestinal epithelial cells (IECs) of orally immunized infected sows could be transferred to CD3+ T cells located just beneath the IECs. Next, PEDV-carrying CD3+ T cells, with the expression of integrin α4ß7 and CCR10, migrate from the intestine to the mammary gland through blood circulation. Arriving in the mammary gland, PEDV-carrying CD3+ T cells could be transported across mammary epithelial cells (MECs) into the lumen (colostrum), as illustrated by an autotransfusion assay and an MECs/T coculture system. The PEDV-carrying CD3+ T cells in colostrum could be interspersed between IECs of neonatal piglets, causing intestinal infection via cell-to-cell contact. Our study demonstrates for the first time that colostrum-derived CD3+ T cells comprise a potential route for the vertical transmission of PEDV. IMPORTANCE The colostrum represents an important infection route for many viruses. Here, we demonstrate the vertical transmission of porcine epidemic diarrhea virus (PEDV) from sows to neonatal piglets via colostrum. PEDV colonizing the intestinal epithelial cells could transfer the virus to CD3+ T cells located in the sow intestine. The PEDV-carrying CD3+ T cells in the sow intestine, with the expression of integrin α4ß7 and CCR10, arrive at the mammary gland through blood circulation and are transported across mammary epithelial cells into the lumen, finally leading to intestinal infection via cell-to-cell contact in neonatal piglets. Our study not only demonstrates an alternative route of PEDV infection but also provides an animal model of vertical transmission of human infectious disease.
Sujets)
Colostrum , Infections à coronavirus , Transmission verticale de maladie infectieuse , Virus de la diarrhée porcine épidémique , Maladies des porcs , Animaux , Animaux nouveau-nés , Colostrum/virologie , Infections à coronavirus/transmission , Infections à coronavirus/médecine vétérinaire , Femelle , Transmission verticale de maladie infectieuse/médecine vétérinaire , Virus de la diarrhée porcine épidémique/physiologie , Suidae , Maladies des porcs/transmission , Maladies des porcs/virologie , Lymphocytes T/virologieRésumé
Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2. To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants, we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine, followed by challenging with emerging SARS-CoV-2 variants of concern (VOCs). These vaccinated animals produced neutralizing antibodies against Alpha, Beta, Delta, and Omicron variants, although there were certain declinations of geometric mean titer (GMT) as compared with prototypic SARS-CoV-2. Of note, in vivo this prototypic vaccine not only reduced the viral loads in nasal, throat and anal swabs, pulmonary tissues, but also improved the pathological changes in the lung infected by variants of Alpha, Beta, and Delta. In summary, the prototypic SARS-CoV-2 inactivated vaccine in this study protected against VOCs to certain extension, which is of great significance for prevention and control of COVID-19.
Sujets)
Anticorps neutralisants/biosynthèse , Anticorps antiviraux/biosynthèse , Vaccins contre la COVID-19/administration et posologie , COVID-19/prévention et contrôle , Protection croisée , SARS-CoV-2/effets des médicaments et des substances chimiques , Vaccination/méthodes , Vaccins inactivés/administration et posologie , Canal anal/virologie , Animaux , Lymphocytes B/immunologie , Lymphocytes B/virologie , COVID-19/immunologie , COVID-19/virologie , Humains , Immunogénicité des vaccins , Poumon/virologie , Macaca mulatta , Mâle , Fosse nasale/virologie , Pharynx/virologie , SARS-CoV-2/croissance et développement , SARS-CoV-2/pathogénicité , Lymphocytes T/immunologie , Lymphocytes T/virologie , Charge virale/effets des médicaments et des substances chimiquesRésumé
SARS-CoV-2 vaccines pose as the most effective approach for mitigating the COVID-19 pandemic. High-degree efficacy of SARS-CoV-2 vaccines in clinical trials indicates that vaccination invariably induces an adaptive immune response. However, the emergence of breakthrough infections in vaccinated individuals suggests that the breadth and magnitude of vaccine-induced adaptive immune response may vary. We assessed vaccine-induced SARS-CoV-2 T cell response in 21 vaccinated individuals and found that SARS-CoV-2-specific T cells, which were mainly CD4+ T cells, were invariably detected in all individuals but the response was varied. We then investigated differentiation states and cytokine profiles to identify immune features associated with superior recall function and longevity. We identified SARS-CoV-2-specific CD4+ T cells were polyfunctional and produced high levels of IL-2, which could be associated with superior longevity. Based on the breadth and magnitude of vaccine-induced SARS-CoV-2 response, we identified 2 distinct response groups: individuals with high abundance versus low abundance of SARS-CoV-2-specific T cells. The fractions of TNF-α- and IL-2-producing SARS-CoV-2 T cells were the main determinants distinguishing high versus low responders. Last, we identified that the majority of vaccine-induced SARS-CoV-2 T cells were reactive against non-mutated regions of mutant S-protein, suggesting that vaccine-induced SARS-CoV-2 T cells could provide continued protection against emerging variants of concern.
Sujets)
Vaccins contre la COVID-19 , COVID-19 , Lymphocytes T , COVID-19/immunologie , COVID-19/prévention et contrôle , Vaccins contre la COVID-19/immunologie , Humains , Immunité cellulaire , Interleukine-2 , Pandémies , SARS-CoV-2 , Lymphocytes T/virologieRésumé
The adaptive immune response is a major determinant of the clinical outcome after SARS-CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and correlate with protection but are relatively impaired in severe disease and are associated with intense activation and lymphopenia. A subset of T cells primed against seasonal coronaviruses cross reacts with SARS-CoV-2 and may contribute to clinical protection, particularly in early life. T cell memory encompasses broad recognition of viral proteins, estimated at around 30 epitopes within each individual, and seems to be well sustained so far. This breadth of recognition can limit the impact of individual viral mutations and is likely to underpin protection against severe disease from viral variants, including Omicron. Current COVID-19 vaccines elicit robust T cell responses that likely contribute to remarkable protection against hospitalization or death, and novel or heterologous regimens offer the potential to further enhance cellular responses. T cell immunity plays a central role in the control of SARS-CoV-2 and its importance may have been relatively underestimated thus far.
Sujets)
COVID-19/immunologie , Immunité cellulaire , Activation des lymphocytes , SARS-CoV-2/immunologie , Lymphocytes T/immunologie , Animaux , Antigènes viraux/immunologie , COVID-19/métabolisme , COVID-19/virologie , Réactions croisées , Interactions hôte-pathogène , Humains , Mémoire immunologique , Phénotype , SARS-CoV-2/génétique , SARS-CoV-2/pathogénicité , Lymphocytes T/métabolisme , Lymphocytes T/virologieRésumé
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to age- and gender-matched recovered individuals without LC, unexposed donors and individuals infected with other coronaviruses. Patients with LC had highly activated innate immune cells, lacked naive T and B cells and showed elevated expression of type I IFN (IFN-ß) and type III IFN (IFN-λ1) that remained persistently high at 8 months after infection. Using a log-linear classification model, we defined an optimal set of analytes that had the strongest association with LC among the 28 analytes measured. Combinations of the inflammatory mediators IFN-ß, PTX3, IFN-γ, IFN-λ2/3 and IL-6 associated with LC with 78.5-81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment.
Sujets)
Lymphocytes B/immunologie , COVID-19/complications , Immunité innée , SARS-CoV-2/immunologie , Lymphocytes T/immunologie , Adulte , Sujet âgé , Lymphocytes B/métabolisme , Lymphocytes B/virologie , Marqueurs biologiques/sang , COVID-19/sang , COVID-19/immunologie , COVID-19/virologie , Études cas-témoins , Cytokines/sang , Femelle , Interactions hôte-pathogène , Humains , Médiateurs de l'inflammation/sang , Mâle , Adulte d'âge moyen , Pronostic , SARS-CoV-2/pathogénicité , Indice de gravité de la maladie , Lymphocytes T/métabolisme , Lymphocytes T/virologie , Facteurs temps ,Résumé
Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we characterize the dynamics of anti-viral immunity during long-term follow-up and after BNT162b2 mRNA-vaccination in convalescents after asymptomatic or mild SARS-CoV-2 infection. Virus-specific and virus-neutralizing antibody titers rapidly declined in convalescents over 9 months after infection, whereas virus-specific cytokine-producing polyfunctional T cells persisted, among which IL-2-producing T cells correlated with virus-neutralizing antibody titers. Among convalescents, 5% of individuals failed to mount long-lasting immunity after infection and showed a delayed response to vaccination compared to 1% of naïve vaccinees, but successfully responded to prime/boost vaccination. During the follow-up period, 8% of convalescents showed a selective increase in virus-neutralizing antibody titers without accompanying increased frequencies of circulating SARS-CoV-2-specific T cells. The same convalescents, however, responded to vaccination with simultaneous increase in antibody and T cell immunity revealing the strength of mRNA-vaccination to increase virus-specific immunity in convalescents.
Sujets)
Vaccin BNT162/immunologie , COVID-19/immunologie , Convalescence , Nucléocapside/immunologie , SARS-CoV-2/immunologie , Glycoprotéine de spicule des coronavirus/immunologie , Anticorps neutralisants/immunologie , Anticorps antiviraux/immunologie , Vaccin BNT162/administration et posologie , COVID-19/virologie , Cytokines/immunologie , Cytokines/métabolisme , Cytométrie en flux/méthodes , Études de suivi , Humains , Immunoglobuline G/immunologie , Interleukine-2/immunologie , Interleukine-2/métabolisme , Cinétique , SARS-CoV-2/physiologie , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Lymphocytes T/virologie , Facteurs temps , Vaccination/méthodesSujets)
Vaccins contre la COVID-19/administration et posologie , COVID-19/prévention et contrôle , Immunité cellulaire/effets des médicaments et des substances chimiques , Calendrier vaccinal , Immunogénicité des vaccins , SARS-CoV-2/effets des médicaments et des substances chimiques , Glycoprotéine de spicule des coronavirus/immunologie , Transplantation de cellules souches , Lymphocytes T/effets des médicaments et des substances chimiques , Adulte , Sujet âgé , Anticorps antiviraux/sang , Vaccin BNT162 , COVID-19/immunologie , COVID-19/virologie , Vaccin ChAdOx1 nCoV-19 , Cytokines/sang , Femelle , Humains , Immunoglobuline G/sang , Activation des lymphocytes/effets des médicaments et des substances chimiques , Mâle , Adulte d'âge moyen , SARS-CoV-2/immunologie , SARS-CoV-2/pathogénicité , Lymphocytes T/immunologie , Lymphocytes T/virologie , Facteurs temps , Transplantation homologue , Résultat thérapeutique , VaccinationRésumé
Coronavirus disease 2019 (COVID-19) is a global infectious disease caused by the SARS-CoV-2 coronavirus. T cells play an essential role in the body's fighting against the virus invasion, and the T cell receptor (TCR) is crucial in T cell-mediated virus recognition and clearance. However, little has been known about the features of T cell response in convalescent COVID-19 patients. In this study, using 5'RACE technology and PacBio sequencing, we analyzed the TCR repertoire of COVID-19 patients after recovery for 2 weeks and 6 months compared with the healthy donors. The TCR clustering and CDR3 annotation were exploited to discover groups of patient-specific TCR clonotypes with potential SARS-CoV-2 antigen specificities. We first identified CD4+ and CD8+ T cell clones with certain clonal expansion after infection, and then observed the preferential recombination usage of V(D) J gene segments in CD4+ and CD8+ T cells of COVID-19 patients with different convalescent stages. More important, the TRBV6-5-TRBD2-TRBJ2-7 combination with high frequency was shared between CD4+ T and CD8+ T cells of different COVID-19 patients. Finally, we found the dominant characteristic motifs of the CDR3 sequence between recovered COVID-19 and healthy control. Our study provides novel insights on TCR in COVID-19 with different convalescent phases, contributing to our understanding of the immune response induced by SARS-CoV-2.
Sujets)
COVID-19/immunologie , Séquençage nucléotidique à haut débit/méthodes , Immunité/immunologie , Récepteurs aux antigènes des cellules T/immunologie , SARS-CoV-2/immunologie , Lymphocytes T/immunologie , Sujet âgé , Séquence d'acides aminés , Lymphocytes T CD4+/immunologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD4+/virologie , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/métabolisme , Lymphocytes T CD8+/virologie , COVID-19/métabolisme , COVID-19/virologie , Cellules cultivées , Régions déterminant la complémentarité/génétique , Régions déterminant la complémentarité/immunologie , Convalescence , Femelle , Humains , Mâle , Adulte d'âge moyen , Acuité des besoins du patient , Récepteurs aux antigènes des cellules T/génétique , Récepteurs aux antigènes des cellules T/métabolisme , Récepteur lymphocytaire T antigène, alpha-bêta/génétique , Récepteur lymphocytaire T antigène, alpha-bêta/immunologie , Récepteur lymphocytaire T antigène, alpha-bêta/métabolisme , SARS-CoV-2/physiologie , Lymphocytes T/métabolisme , Lymphocytes T/virologieRésumé
The response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely impacted by the level of virus exposure and status of the host immunity. The nature of protection shown by direct asymptomatic contacts of coronavirus disease 2019 (COVID-19)-positive patients is quite intriguing. In this study, we have characterized the antibody titer, SARS-CoV-2 surrogate virus neutralization, cytokine levels, single-cell T-cell receptor (TCR), and B-cell receptor (BCR) profiling in asymptomatic direct contacts, infected cases, and controls. We observed significant increase in antibodies with neutralizing amplitude in asymptomatic contacts along with cytokines such as Eotaxin, granulocyte-colony stimulating factor (G-CSF), interleukin 7 (IL-7), migration inhibitory factor (MIF), and macrophage inflammatory protein-1α (MIP-1α). Upon single-cell RNA (scRNA) sequencing, we explored the dynamics of the adaptive immune response in few representative asymptomatic close contacts and COVID-19-infected patients. We reported direct asymptomatic contacts to have decreased CD4+ naive T cells with concomitant increase in CD4+ memory and CD8+ Temra cells along with expanded clonotypes compared to infected patients. Noticeable proportions of class switched memory B cells were also observed in them. Overall, these findings gave an insight into the nature of protection in asymptomatic contacts.
Sujets)
Immunité acquise/immunologie , COVID-19/immunologie , Génomique/méthodes , SARS-CoV-2/immunologie , Analyse sur cellule unique/méthodes , Immunité acquise/génétique , Adulte , Anticorps antiviraux/immunologie , COVID-19/génétique , COVID-19/virologie , Cytokines/immunologie , Cytokines/métabolisme , Femelle , Analyse de profil d'expression de gènes/méthodes , Humains , Mâle , Cellules B mémoire/immunologie , Cellules B mémoire/métabolisme , Cellules B mémoire/virologie , Adulte d'âge moyen , SARS-CoV-2/physiologie , Analyse de séquence d'ARN/méthodes , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Lymphocytes T/virologie , Jeune adulteRésumé
The systemic processes involved in the manifestation of life-threatening COVID-19 and in disease recovery are still incompletely understood, despite investigations focusing on the dysregulation of immune responses after SARS-CoV-2 infection. To define hallmarks of severe COVID-19 in acute disease (n = 58) and in disease recovery in convalescent patients (n = 28) from Hannover Medical School, we used flow cytometry and proteomics data with unsupervised clustering analyses. In our observational study, we combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and injury. ICU patients displayed an altered immune signature with prolonged lymphopenia but the expansion of granulocytes and plasmablasts along with activated and terminally differentiated T and NK cells and high levels of SARS-CoV-2-specific antibodies. The core signature of seven plasma proteins revealed a highly inflammatory microenvironment in addition to endothelial injury in severe COVID-19. Changes within this signature were associated with either disease progression or recovery. In summary, our data suggest that besides a strong inflammatory response, severe COVID-19 is driven by endothelial activation and barrier disruption, whereby recovery depends on the regeneration of the endothelial integrity.
Sujets)
Anticorps antiviraux/sang , Protéines du sang/métabolisme , COVID-19/diagnostic , Syndrome de libération de cytokines/diagnostic , Endothélium vasculaire/virologie , Lymphopénie/diagnostic , SARS-CoV-2/pathogénicité , Marqueurs biologiques/sang , Protéine C-réactive/métabolisme , COVID-19/immunologie , COVID-19/mortalité , COVID-19/virologie , Chimiokine CXCL10/sang , Chimiokine CXCL9/sang , Analyse de regroupements , Convalescence , Syndrome de libération de cytokines/immunologie , Syndrome de libération de cytokines/mortalité , Syndrome de libération de cytokines/virologie , Évolution de la maladie , Endothélium vasculaire/immunologie , Granulocytes/immunologie , Granulocytes/virologie , Facteurs de croissance hématopoïétique/sang , Facteur de croissance des hépatocytes/sang , Humains , Unités de soins intensifs , Sous-unité p40 de l'interleukine-12/sang , Interleukine-6/sang , Interleukine-8/sang , Cellules tueuses naturelles/immunologie , Cellules tueuses naturelles/virologie , Lectines de type C/sang , Lymphopénie/immunologie , Lymphopénie/mortalité , Lymphopénie/virologie , Plasmocytes/immunologie , Plasmocytes/virologie , Analyse de survie , Lymphocytes T/immunologie , Lymphocytes T/virologieRésumé
BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is an acute, febrile, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated syndrome, often with cardiohemodynamic dysfunction. Insight into mechanism of disease is still incomplete. OBJECTIVE: Our objective was to analyze immunologic features of MIS-C patients compared to febrile controls (FC). METHODS: MIS-C patients were defined by narrow criteria, including having evidence of cardiohemodynamic involvement and no macrophage activation syndrome. Samples were collected from 8 completely treatment-naive patients with MIS-C (SARS-CoV-2 serology positive), 3 patients with unclassified MIS-C-like disease (serology negative), 14 FC, and 5 MIS-C recovery (RCV). Three healthy controls (HCs) were used for comparisons of normal range. Using spectral flow cytometry, we assessed 36 parameters in antigen-presenting cells (APCs) and 29 in T cells. We used biaxial analysis and uniform manifold approximation and projection (UMAP). RESULTS: Significant elevations in cytokines including CXCL9, M-CSF, and IL-27 were found in MIS-C compared to FC. Classic monocytes and type 2 dendritic cells (DCs) were downregulated (decreased CD86, HLA-DR) versus HCs; however, type 1 DCs (CD11c+CD141+CLEC9A+) were highly activated in MIS-C patients versus FC, expressing higher levels of CD86, CD275, and atypical conventional DC markers such as CD64, CD115, and CX3CR1. CD169 and CD38 were upregulated in multiple monocyte subtypes. CD56dim/CD57-/KLRGhi/CD161+/CD38- natural killer (NK) cells were a unique subset in MIS-C versus FC without macrophage activation syndrome. CONCLUSION: Orchestrated by complex cytokine signaling, type 1 DC activation and NK dysregulation are key features in the pathophysiology of MIS-C. NK cell findings may suggest a relationship with macrophage activation syndrome, while type 1 DC upregulation implies a role for antigen cross-presentation.
Sujets)
COVID-19/complications , Cellules dendritiques/immunologie , Cellules dendritiques/virologie , SARS-CoV-2/immunologie , Syndrome de réponse inflammatoire généralisée/immunologie , Syndrome de réponse inflammatoire généralisée/virologie , Antigènes CD38/sang , Adolescent , Antigènes viraux/immunologie , COVID-19/immunologie , COVID-19/virologie , Études cas-témoins , Enfant , Enfant d'âge préscolaire , Cross-priming , Cytokines/sang , Cellules dendritiques/classification , Femelle , Antigènes HLA-DR/sang , Humains , Immunophénotypage , Interféron gamma/sang , Interleukines/sang , Cellules tueuses naturelles/immunologie , Mâle , Glycoprotéines membranaires/sang , Modèles immunologiques , Monocytes/immunologie , Lectine-1 de type Ig liant l'acide sialique/sang , Lymphocytes T/immunologie , Lymphocytes T/virologie , Régulation positiveSujets)
Vaccins contre la COVID-19/administration et posologie , COVID-19/prévention et contrôle , Immunité cellulaire/effets des médicaments et des substances chimiques , Immunogénicité des vaccins , Myélome multiple/immunologie , SARS-CoV-2/effets des médicaments et des substances chimiques , Glycoprotéine de spicule des coronavirus/immunologie , Vaccin ARNm-1273 contre la COVID-19 , Anticorps antiviraux/sang , Lymphocytes B/effets des médicaments et des substances chimiques , Lymphocytes B/immunologie , Lymphocytes B/virologie , Vaccin BNT162 , COVID-19/diagnostic , COVID-19/immunologie , COVID-19/virologie , Études cas-témoins , Cytokines/sang , Interactions hôte-pathogène , Humains , Immunoglobuline G/sang , Activation des lymphocytes/effets des médicaments et des substances chimiques , Myélome multiple/diagnostic , SARS-CoV-2/immunologie , SARS-CoV-2/pathogénicité , Lymphocytes T/effets des médicaments et des substances chimiques , Lymphocytes T/immunologie , Lymphocytes T/virologie , Résultat thérapeutique , VaccinationRésumé
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable neutralizing antibody titers (NAbT) against SARS-CoV-2 variants of concern (VOCs) vs wildtype (WT). Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT vs solid cancers against both WT and VOCs. In comparison with individuals without cancer, patients with haematological, but not solid, malignancies had reduced NAb responses. Seroconversion showed poor concordance with NAbT against VOCs. Prior SARS-CoV-2 infection boosted NAb response including against VOCs, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T-cell responses were detected in 80% of patients, and were comparable between vaccines or cancer types. Our results have implications for the management of cancer patients during the ongoing COVID-19 pandemic.
Sujets)
Immunité acquise/immunologie , Anticorps neutralisants/immunologie , Vaccins contre la COVID-19/immunologie , COVID-19/immunologie , Néphrocarcinome/complications , Tumeurs du rein/complications , SARS-CoV-2/immunologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Vaccin BNT162/administration et posologie , Vaccin BNT162/immunologie , COVID-19/complications , COVID-19/épidémiologie , Vaccins contre la COVID-19/administration et posologie , Vaccin ChAdOx1 nCoV-19/administration et posologie , Vaccin ChAdOx1 nCoV-19/immunologie , Femelle , Humains , Immunogénicité des vaccins/immunologie , Études longitudinales , Mâle , Adulte d'âge moyen , Pandémies/prévention et contrôle , Études prospectives , SARS-CoV-2/génétique , SARS-CoV-2/physiologie , Lymphocytes T/immunologie , Lymphocytes T/virologie , Vaccination/méthodesRésumé
Nascent HIV-1 particles incorporate the viral envelope glycoprotein and multiple host transmembrane proteins during assembly at the plasma membrane. At least some of these host transmembrane proteins on the surface of virions are reported as pro-viral factors that enhance virus attachment to target cells or facilitate trans-infection of CD4+ T cells via interactions with non-T cells. In addition to the pro-viral factors, anti-viral transmembrane proteins are incorporated into progeny virions. These virion-incorporated transmembrane proteins inhibit HIV-1 entry at the point of attachment and fusion. In infected polarized CD4+ T cells, HIV-1 Gag localizes to a rear-end protrusion known as the uropod. Regardless of cell polarization, Gag colocalizes with and promotes the virion incorporation of a subset of uropod-directed host transmembrane proteins, including CD162, CD43, and CD44. Until recently, the functions of these virion-incorporated proteins had not been clear. Here, we review the recent findings about the roles played by virion-incorporated CD162, CD43, and CD44 in HIV-1 spread to CD4+ T cells.
Sujets)
Infections à VIH/métabolisme , Antigènes CD44/métabolisme , Antigènes CD43/métabolisme , Glycoprotéines membranaires/métabolisme , Membrane cellulaire/métabolisme , Infections à VIH/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/génétique , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/métabolisme , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/pathogénicité , Interactions hôte-pathogène , Humains , Antigènes CD44/génétique , Antigènes CD43/génétique , Glycoprotéines membranaires/génétique , Protéines membranaires/métabolisme , Lymphocytes T/métabolisme , Lymphocytes T/virologie , Virion/métabolisme , Assemblage viral , Attachement viral , Produits du gène gag du virus de l'immunodéficience humaine/métabolismeRésumé
SARS-CoV-2 has caused morbidity and mortality across the globe. As the virus spreads, new variants are arising that show enhanced capacity to bypass preexisting immunity. To understand the memory response to SARS-CoV-2, here, we monitored SARS-CoV-2specific T and B cells in a longitudinal study of infected and recovered golden hamsters (Mesocricetus auratus). We demonstrated that engagement of the innate immune system after SARS-CoV-2 infection was delayed but was followed by a pronounced adaptive response. Moreover, T cell adoptive transfer conferred a reduction in virus levels and rapid induction of SARS-CoV-2specific B cells, demonstrating that both lymphocyte populations contributed to the overall response. Reinfection of recovered animals with a SARS-CoV-2 variant of concern showed that SARS-CoV-2specific T and B cells could effectively control the infection that associated with the rapid induction of neutralizing antibodies but failed to block transmission to both naïve and seroconverted animals. These data suggest that the adaptive immune response to SARS-CoV-2 is sufficient to provide protection to the host, independent of the emergence of variants.
Sujets)
COVID-19/immunologie , Modèles animaux de maladie humaine , Mémoire immunologique/immunologie , SARS-CoV-2/immunologie , Réplication virale/immunologie , Immunité acquise/immunologie , Animaux , Anticorps neutralisants/immunologie , Anticorps antiviraux/immunologie , Lymphocytes B/immunologie , Lymphocytes B/virologie , COVID-19/virologie , Cricetinae , Interactions hôte-pathogène/immunologie , Humains , Immunité innée/immunologie , Mesocricetus , SARS-CoV-2/génétique , SARS-CoV-2/physiologie , Lymphocytes T/immunologie , Lymphocytes T/virologie , Réplication virale/génétiqueSujets)
Vaccins contre la COVID-19/administration et posologie , COVID-19/prévention et contrôle , Immunité cellulaire/effets des médicaments et des substances chimiques , Immunité humorale/effets des médicaments et des substances chimiques , Calendrier vaccinal , Immunogénicité des vaccins , Tumeurs/immunologie , SARS-CoV-2/effets des médicaments et des substances chimiques , Glycoprotéine de spicule des coronavirus/immunologie , Anticorps antiviraux/sang , Vaccin BNT162 , COVID-19/diagnostic , COVID-19/immunologie , COVID-19/virologie , Études cas-témoins , Cytokines/sang , Interactions hôte-pathogène , Humains , Immunoglobuline G/sang , SARS-CoV-2/immunologie , SARS-CoV-2/pathogénicité , Lymphocytes T/effets des médicaments et des substances chimiques , Lymphocytes T/immunologie , Lymphocytes T/virologie , Facteurs temps , Résultat thérapeutique , VaccinationSujets)
Anticorps neutralisants/composition chimique , COVID-19/virologie , Tests de neutralisation , SARS-CoV-2/génétique , SARS-CoV-2/physiologie , Animaux , Vaccins contre la COVID-19 , Chlorocebus aethiops , Bases de données génétiques , Humains , Mutation , Glycoprotéine de spicule des coronavirus/immunologie , Lymphocytes T/immunologie , Lymphocytes T/virologie , Cellules Vero , VietnamSujets)
Anticorps antiviraux/sang , Vaccins contre la COVID-19/administration et posologie , COVID-19/prévention et contrôle , Immunogénicité des vaccins , Transplantation rénale/effets indésirables , SARS-CoV-2/immunologie , Glycoprotéine de spicule des coronavirus/immunologie , Lymphocytes T/effets des médicaments et des substances chimiques , Vaccination , Adulte , Sujet âgé , Vaccin BNT162 , Belgique , COVID-19/immunologie , COVID-19/virologie , Femelle , Humains , Immunité humorale/effets des médicaments et des substances chimiques , Calendrier vaccinal , Sujet immunodéprimé , Immunosuppresseurs/effets indésirables , Interféron gamma/métabolisme , Activation des lymphocytes/effets des médicaments et des substances chimiques , Mâle , Adulte d'âge moyen , Études prospectives , SARS-CoV-2/pathogénicité , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Lymphocytes T/virologie , Facteurs tempsSujets)
Vaccins contre la COVID-19/immunologie , COVID-19/immunologie , COVID-19/prévention et contrôle , SARS-CoV-2/immunologie , Lymphocytes T/immunologie , Lymphocytes T/virologie , Anticorps antiviraux/immunologie , Lymphocytes T CD4+/cytologie , Lymphocytes T CD8+/cytologie , Cytokines/métabolisme , Humains , Système immunitaire , Immunité , Immunoglobuline G , Peptides/composition chimique , SARS-CoV-2/génétiqueRésumé
T-cell-mediated immunity to SARS-CoV-2-derived peptides in individuals unexposed to SARS-CoV-2 has been previously reported. This pre-existing immunity was suggested to largely derive from prior exposure to 'common cold' endemic human coronaviruses (HCoVs). To test this, we characterised the sequence homology of SARS-CoV-2-derived T-cell epitopes reported in the literature across the full proteome of the Coronaviridae family. 54.8% of these epitopes had no homology to any of the HCoVs. Further, the proportion of SARS-CoV-2-derived epitopes with any level of sequence homology to the proteins encoded by any of the coronaviruses tested is well-predicted by their alignment-free phylogenetic distance to SARS-CoV-2 (Pearson's r = -0.958). No coronavirus in our dataset showed a significant excess of T-cell epitope homology relative to the proportion of expected random matches, given their genetic similarity to SARS-CoV-2. Our findings suggest that prior exposure to human or animal-associated coronaviruses cannot completely explain the T-cell repertoire in unexposed individuals that recognise SARS-CoV-2 cross-reactive epitopes.